Hyperhidrosis Treatment Market | Competitive Strategies And Forecasts to 2025

Hyperhidrosis, a disorder characterized by excessive sweating, can be focal or generalized. The severity of hyperhidrosis can vary from slight wetness to severe wet and can cause significant damage to the quality of life, which includes limitations in social and work relationships, leisure, and physical activities. It can even impact mental and emotional health. Hyperhidrosis can occur due to medical conditions such as diabetes, injury, such as head trauma caused by an accident, menopause, obesity, and overactive thyroid (hyperthyroidism). It affects multiple body parts, most frequently the armpits, palms, face or soles. Nearly 3% of the population, mostly individuals aged between 25 and 64 years, suffer from hyperhidrosis. Hyperhidrosis brings a significant social and psychological burden, as it hampers daily activities. However, individuals suffering from this disorder rarely seek medical help, as several patients are unaware that they are suffering from a treatable medical disorder. Primary recognition and managing of hyperhidrosis can significantly recover a patient’s quality of life. There are several systemic, topical, surgical and nonsurgical treatments available with effectiveness rates ranging between 90% and 95%.
Read Report Overview - https://www.transparencymarketresearch.com/hyperhidrosis-treatment-market.html
The global market of hyperhidrosis can be segmented based on type, treatment, end user, and geography. Based on type, the hyperhidrosis market can be classified into generalized and focal. Generalized hyperhidrosis includes the complete body and is generally a part of the primary condition, most often an endocrine, infectious, or neurologic disorder. Focal hyperhidrosis is idiopathic, arising in healthy people. Based on treatment, the hyperhidrosis market can be segregated into topical treatments, Iontophoresis, Botulinum toxin A, surgical treatments, and systemic treatments. Topical treatment includes aluminum salts, which is the most common over-the-counter ingredient in antiperspirants that are utilized to treat focal hyperhidrosis. Moreover, aldehyde agents such as glutaraldehyde and formaldehyde are also employed to treat hyperhidrosis as topical treatments. Iontophoresis is the diffusion of ions into the skin by means of an electrical current. Botulinum toxin A is used to treat hyperhidrosis, which is a form of neurotoxin produced by the anaerobic bacterium Clostridium botulinum. Surgical treatments comprise endoscopic thoracic sympathectomy that terminates the sympathetic ganglia by clamping, excision, ablation, or transection with laser or cautery. The systemic treatment includes anticholinergic agents that inhibit synaptic acetylcholine, they interfere with neuroglandular signaling. Based on distribution channel, the global market for hyperhidrosis can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
In terms of geography, the hyperhidrosis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Furthermore, the North America hyperhidrosis market can be segmented into U.S., and Canada. The Europe hyperhidrosis market can be segregated into U.K., Germany, France, Italy, Spain, and Rest of Europe. The Asia Pacific Hyperhidrosis market can be further segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. The Latin America hyperhidrosis market can be segmented into Mexico, Brazil, and Rest of Latin America. Where Middle East and Africa hyperhidrosis market is segmented into Saudi Arabia, South Africa, Israel, and Rest of Middle East and Africa. North America dominates the global hyperhidrosis market, followed by Europe. The prime factors that can be attributed to the expansion of the market in these regions are rising awareness about hyperhidrosis among the adult population and availability of sophisticated and technologically advanced treatment options. According to statistics published by International Hyperhidrosis Society, The U.S. has a prominent number of hyperhidrosis cases among the major developed countries. The stated prevalence rate for hyperhidrosis in the U.S. is about 4.8%. Hyperhidrosis affects nearly 15 million people in the U.S., and approximately 5% of the global population.
Key players operating in the global hyperhidrosis market include Allergan, Miramar Labs, Inc., Brickell Biotech, Inc., Dermira, Inc., Revance Therapeutics, Inc., GlaxoSmithKline plc, and TheraVida.

Comments

Post a Comment